Search Clinical Trials
Sponsor Condition of Interest |
---|
Probiotic Use for Recovery Enhancement from Long COVID-19
Rush University Medical Center
Post-Acute COVID-19 Syndrome
The goal of this clinical trial is to learn if probiotics can improve symptoms and
quality of life in participants with Long COVID. The main questions it aims to answer
are:
1. Do probiotics reduce the number and severity of symptoms in those with Long COVID?
2. Do probiotics improve physical... expand
The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID. The main questions it aims to answer are: 1. Do probiotics reduce the number and severity of symptoms in those with Long COVID? 2. Do probiotics improve physical and mental health quality of life in those with Long COVID? 3. Do probiotics improve return to work and daily activities in those with Long COVID? Researchers will compare probiotics to a placebo (a look-alike substance that contains no probiotics) to see if probiotics works to treat Long COVID. Participants will take the study medication (placebo or probiotic) for 4 months. They will then cross-over (take the other medication) for an additional 4 months. Participants will complete a survey at baseline, 4 months, and 8 months. Type: Interventional Start Date: Dec 2024 |
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19...
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled
study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of
IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic
tachycardia syndrome (post-Coronavirus Disease... expand
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 [COVID-19] POTS [post-COVID-POTS]). Type: Interventional Start Date: Aug 2024 |
Efficacy and Safety Study of Efgartigimod in Adults with Post-COVID-19 POTS
argenx
Postural Orthostatic Tachycardia Syndrome
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD),
pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in
participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS)
(post-COVID-19 POTS). expand
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS). Type: Interventional Start Date: Sep 2022 |
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease...
University of Minnesota
COVID-19
Treatments are needed to improve outcomes among patients hospitalized for COVID-19,
including direct-acting antiviral (DAA) agents to mitigate the pathology driven by
ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an
anti-SARS-CoV2 3C-like protease inhibitor (PI) developed... expand
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization. Type: Interventional Start Date: Dec 2022 |
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
Pfizer
COVID-19
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which
contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as
its safety, and the extent to which side effects can be tolerated for treatment of
pregnant women with mild or moderate... expand
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects can be tolerated for treatment of pregnant women with mild or moderate COVID-19 compared to non-pregnant women with mild or moderate COVID-19. This study is seeking participants who: - are expecting a healthy baby and are in their second or third trimester pregnancy and have mild or moderate COVID-19 - are not pregnant and have mild or moderate COVID-19. All participants in this study will take Paxlovid by mouth every 12 hours for 5 days. We will study the experiences of people receiving the study medicine. This will help us decide if the study medicine is safe. All participants will take part in this study for at least 34 days; pregnant participants will take part until their delivery, so that the study duration may be up to 6 months, depending on their delivery date. During this time, participants will have 7to 8 visits and, if pregnant, a visit at delivery. Around 2 to 3 visits and the delivery visit will be done in person (at the clinic or at the participant's home). The other 5 visits may be done over the phone, unless in-person visit is necessary as decided by the doctor. Blood samples will be collected on the first 4 to 5 study visits (and at other study visits, if necessary). Type: Interventional Start Date: Jun 2022 |
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients...
Pfizer
COVID-19
The purpose of this clinical trial is to learn about the safety, pharmacokinetics
(pharmacokinetics helps us understand how the drug is changed and eliminated from your
body after you take it), and efficacy (how well a study treatment works in the study) of
the study medicine (called nirmatrelvir/ritonavir)... expand
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease. Type: Interventional Start Date: Mar 2022 |
Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency...
M.D. Anderson Cancer Center
COVID-19 Infection
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
This study investigates patients' perceptions of their doctor's or nurse's empathy during
an in-person interaction with the doctor or nurse wearing personal protective equipment
(PPE) compared to during a video interaction with the doctor or nurse without PPE. The
goal of this research study is to... expand
This study investigates patients' perceptions of their doctor's or nurse's empathy during an in-person interaction with the doctor or nurse wearing personal protective equipment (PPE) compared to during a video interaction with the doctor or nurse without PPE. The goal of this research study is to learn whether patients who visit the Acute Cancer Care Center at MD Anderson believe they get better (more empathetic) care from doctors who visit them in person wearing PPE or from doctors who visit them by video call and do not wear PPE. Type: Observational Start Date: Jun 2021 |
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of...
Sanofi Pasteur, a Sanofi Company
COVID-19
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity
of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series
vaccinations in a multi-stage approach, as well as a booster injection of a CoV2 preS
dTM-AS03 vaccine, in adults 18 years... expand
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a booster injection of a CoV2 preS dTM-AS03 vaccine, in adults 18 years of age and older. A total of approximately 21 046 participants are planned to be enrolled (5080 per study intervention group in Stage 1 and 5443 per study intervention group in Stage 2). Initial, double-blind, primary series study design is planned for 365 days post-last Initial injection (ie, approximately 386 days total) for each participant. Based on decisions of the Study Oversight Group, Stage 1 and Stage 2 participants will be invited to participate in an unblinded Crossover / Booster study design with duration as follows: - For participants who initially received vaccine: 12 months post-booster (ie, approximately 18 to 24 months) - For participants who initially received placebo: ≥ 4 months post-last dose of the primary series + 12 months post-booster (ie, approximately 28 to 34 months) - For participants who do not consent to continue in the unblinded Crossover / Booster part of the study, all study procedures will be stopped and participants will be discontinued from the study. Type: Interventional Start Date: Aug 2020 |
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants...
BioNTech SE
SARS-CoV-2 Infection, COVID19
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are
considered to be participants 18 years of age or older. Participants are going to be
enrolled based on conditions that make them immunocompromised. Participants are going to
be followed up for 6 months after dose 4,... expand
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, and each participant is projected to be on the study for approximately 15 months. This study will be conducted in the United States, Brazil, Germany and Mexico. Type: Interventional Start Date: Oct 2021 |
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
Vanderbilt University Medical Center
COVID 19
Nasal saline irrigations are a safe and commonly used mechanism to treat a variety of
sinonasal diseases including sinusitis, rhinitis, and upper respiratory tract infections.
When used properly, these irrigations are a safe and easy intervention available over the
counter without a prescription.... expand
Nasal saline irrigations are a safe and commonly used mechanism to treat a variety of sinonasal diseases including sinusitis, rhinitis, and upper respiratory tract infections. When used properly, these irrigations are a safe and easy intervention available over the counter without a prescription. Additionally, baby shampoo has been found to be a safe additive functioning as a surfactant when a small amount is added to the saline rinses which may help augment clearance of the sinonasal cavity. While many systemic medications and treatments have been proposed for COVID-19, there has not yet been a study looking at targeted local intervention to the nasal cavity and nasopharynx where the viral load is the highest. Studies have shown that the use of simple over the counter nasal saline irrigations can decrease viral shedding in the setting of viral URIs, including the common coronavirus (not SARS-CoV-2). Further, as SARS-CoV-2 is an enveloped virus, mild-detergent application with nasal saline would neutralize the virus further. It is our hypothesis that nasal saline or nasal saline with baby shampoo irrigations may decrease viral shedding/viral load and viral transmission, secondary bacterial load, nasopharyngeal inflammation in patients infected with the novel SARS-CoV-2. Type: Interventional Start Date: May 2020 |
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19...
Baylor College of Medicine
Sars-CoV2
Acute Respiratory Distress Syndrome
COVID-19
***At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College
of Medicine (BCM) and are not shipping cells outside of BCM/HMH.***
This is a study for patients who have respiratory infection caused by SARS-CoV-2 that
have not gotten better. Because there is no standard... expand
***At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.*** This is a study for patients who have respiratory infection caused by SARS-CoV-2 that have not gotten better. Because there is no standard treatment for this infection, patients are being asked to volunteer for a gene transfer research study using mesenchymal stem cells (MSCs). Stem cells are cells that do not yet have a specific function in the body. Mesenchymal stem cells (MSCs) are a type of stem cell that can be grown from bone marrow (the spongy tissue inside of bones). Stem cells can develop into other types of more mature (specific) cells, such as blood and muscle cells. The purpose of this study is to see if MSCs versus controls can help to treat respiratory infections caused by SARS-CoV-2. Type: Interventional Start Date: Feb 2021 |
DiaBetter Together for Young Adults with Type 1 Diabetes
Baylor College of Medicine
Type 1 Diabetes
DiaBetter Together is a strengths-based peer support intervention delivered to young
adults (age 17-25) by trained Peer Mentors (age 20-35) during the transition between
pediatric and adult diabetes care. The aims of this proposed randomized controlled trial
are to evaluate the impact of the intervention... expand
DiaBetter Together is a strengths-based peer support intervention delivered to young adults (age 17-25) by trained Peer Mentors (age 20-35) during the transition between pediatric and adult diabetes care. The aims of this proposed randomized controlled trial are to evaluate the impact of the intervention on glycemic control (primary), time to first adult care visit, adherence, and psychosocial outcomes (secondary) in young adults with T1D after 12 months. Type: Interventional Start Date: Dec 2020 |
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
National Institute on Aging (NIA)
COVID-19
Background:
The immune response is how the body recognizes and defends itself against foreign and
harmful substances. Researchers want to compare the immune responses between young and
older healthy adults after they receive vaccine doses for COVID-19. This research may
help to determine whether... expand
Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive vaccine doses for COVID-19. This research may help to determine whether age impacts cell response to COVID-19 vaccines. Objective: To study the immune response of people who receive Pizer or Moderna COVID-19 vaccines. Eligibility: People aged 18 and older who have not had COVID-19 and who either plan to receive the first dose of a COVID-19 vaccine within the next month or have received at least the first of 2 doses of the vaccine within the last 6 months. Design: Participants will be screened by telephone. Participants will not get the COVID-19 vaccine in this study. They must get it through a vaccine location. Participants who have not yet been vaccinated will have 7 visits. The first 4 visits will occur in the first month before and after each vaccination. The last 3 visits will occur 6 months, 1 year, and 2 years after completed vaccination. Participants who have received at least 1 of 2 doses of the COVID-19 vaccine within the last 6 months will have 3 visits. The first visit will occur within 6 months of receiving the first vaccine dose. The last 2 visits will occur 1 year and 2 years after the first vaccine dose. At visits, participant will review their medical history. Their height, weight, and/or vital signs will be measured. They will give blood samples after fasting. They may give urine samples. They may have a nasal swab test for COVID-19. Type: Observational Start Date: Apr 2021 |
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved...
National Cancer Institute (NCI)
COVID-19
Background:
People who get infected with COVID-19 have an unpredictable risk to worsen and die. This
makes it hard to decide who can quarantine at home and who should be treated at a
hospital. Researchers think the risk may be related to how a person s B and T cells
respond to the virus. B and... expand
Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T cells are the major components of a person s immune response. B and T cells responding to the virus with a favorable pattern may lead to recovery, and this favorable pattern may be helpful to establish. If people in a vaccine trial get this same favorable pattern when responding to a vaccine, this may be a useful early signal that the vaccine will be successful. Objective: To examine how immune cells respond to COVID-19 infection. Eligibility: Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past. Also, healthy donors with no suspected COVID-19 infection Design: Participants will be screened with medical record review. Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. This test will be used to understand research results, not to advise patients. Participants with active infection must be isolated, usually in a hospital. Other participants may give blood samples at NIH or at their local doctor s office or lab. Participants may give blood samples up to three times a week for a total of ten times, and may also give blood samples after starting a vaccine trial. Participants will be contacted by phone or email every 2 months for up to 2 years. Type: Observational Start Date: Apr 2020 |
Synbiotic Therapy for NP-PASC
Columbia University
Post-Acute COVID-19 Syndrome
Long COVID-19
Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of
Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at
Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid,
remained lower in people with Neuropsychiatric... expand
Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiatric PASC (NP-PASC) than in people with PASC after SAR-CoV-2 infection. Synbiotics improve SCFA levels and are well-tolerated in the general population but have not been studied among people with PASC in the United States. The purpose of this pilot study is to characterize changes in plasma SCFA levels and gut microbiome after treatment with synbiotics and placebo in people with NP-PASC. The intervention will be a mixture of the prebiotic resistant starch and the probiotic Bifidobacterium adolescentis in-vivo selection 1 strain (iVS-1). The placebo will be Maltodextrin. Type: Interventional Start Date: Sep 2024 |
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
University of California, Los Angeles
Long Covid-19
PASC Post Acute Sequelae of COVID 19
Brain Fog
Fatigue
This is a pilot randomized trial of rTMS for symptoms of fatigue and brain fog, and other
neuropsychiatric symptoms of Long-COVID (Post-COVID, post-acute sequelae of COVID-19
infection, PASC). Twenty participants diagnosed with Long-COVID and recruited from the
UCLA Long-COVID clinic will be randomized... expand
This is a pilot randomized trial of rTMS for symptoms of fatigue and brain fog, and other neuropsychiatric symptoms of Long-COVID (Post-COVID, post-acute sequelae of COVID-19 infection, PASC). Twenty participants diagnosed with Long-COVID and recruited from the UCLA Long-COVID clinic will be randomized to receive active rTMS versus sham stimulation for 15 treatments followed by another 15 open-label rTMS treatments. Investigators will compare the safety and tolerability of rTMS vs Sham and examine within-group changes in symptoms of fatigue, sleep, pain, mood, and subjective and objective cognitive impairment. This project will provide information and pilot data for future larger clinical trials. Type: Interventional Start Date: Sep 2024 |
Evaluating Social Perception Dynamics
Yale University
Mental Health Issue
COVID-19
Mental health vulnerability due to stress is increased in People of African Descent
(PADs) in America due to disproportionate effects of racism, poverty, education, and
criminal justice sentencing. Various meditation and mindfulness approaches have provided
evidence of measured reductions in multiple... expand
Mental health vulnerability due to stress is increased in People of African Descent (PADs) in America due to disproportionate effects of racism, poverty, education, and criminal justice sentencing. Various meditation and mindfulness approaches have provided evidence of measured reductions in multiple negative dimensions of stress. However, the majority of these studies do not have an adequate representation of PADs or other marginalized groups and are not designed to be culturally relevant or community based. Music has been shown to alleviate multiple symptoms of stress and has been shown to be a preferred and effective support for meditation and mindfulness. However, its role in stress management in PADs engaged in meditation or mindfulness is seldom studied. This study aims to evaluate the effects of a virtual, community-based music mindfulness program on stress management in PAD community members with anxiety and depression during COVID19. Component 2d. Social Perception Tasks: Participants may be asked to take part in social perception tasks in which they will be asked to indicate their social perception and connection felt with various partners. Type: Interventional Start Date: Aug 2024 |
Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression
City University of New York, School of Public Health
Misinformation
Vaccine Hesitancy
Anxiety
Depression
COVID-19
The COVID-19 pandemic has led to a mis/disinformation ecosystem that promotes divergent
views of vaccine efficacy, as well as the legitimacy of science and medicine. Individuals
are confronted with vaccine-related information from a multitude of sources, posing a
challenge to identifying inaccurate... expand
The COVID-19 pandemic has led to a mis/disinformation ecosystem that promotes divergent views of vaccine efficacy, as well as the legitimacy of science and medicine. Individuals are confronted with vaccine-related information from a multitude of sources, posing a challenge to identifying inaccurate information. COVID-19 vaccine uptake is lower among people with anxiety and depression than in the general population, due in part to higher levels of vaccine hesitancy. The prevalence of anxiety and depressive symptoms among US adults increased significantly during the COVID pandemic and has remained elevated. Interventions capable of mitigating the impact of vaccine hesitancy and mis/disinformation among undervaccinated people with anxiety or depression are therefore an urgent priority. Emerging evidence suggests that reasons for vaccine hesitancy and the impact of conventional vaccination messaging differ between those with and without mental health symptoms. There may also be added challenges overcoming logistical barriers to vaccination for people with anxiety or depressive symptoms. The investigators aim to determine the effectiveness of two different brief digital intervention strategies compared with conventional public health messaging for increasing vaccine uptake in undervaccinated adults with and without anxiety or depressive symptoms. Attitudinal inoculation is a brief, scalable strategy that leverages the power of narrative, values, and emotion to strengthen resistance to mis/disinformation and reduce hesitancy. Though this approach has been shown to decrease COVID-19 vaccine hesitancy among US adults, the extent to which this approach increases COVID-19 vaccination remains unknown. Cognitive-behavioral therapy (CBT) is an evidence-based intervention for anxiety and depression. However, the efficacy of incorporating CBT-informed messaging in a vaccine promotion intervention has not been tested. The investigators hypothesize that both attitudinal inoculation and CBT-style communication will be more effective than conventional public health messaging to increase COVID-19 vaccination. The investigators also hypothesize that the CBT-informed intervention will be more effective than the attitudinal inoculation intervention for increasing COVID-19 vaccination among participants with symptoms of anxiety or depression. Type: Interventional Start Date: Apr 2024 |
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
GlaxoSmithKline
SARS-CoV-2
The purpose of Part A of this study is to assess the immune response and safety of a
booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will
compare the investigational vaccines to control vaccine.
The purpose of Part B of this study is to assess the immune response... expand
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine. The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions. Type: Interventional Start Date: Aug 2023 |
Ventilatory and Perfusion Abnormalities in Individuals with Post-Acute Sequelae of SARS-CoV-2 Infection
Tufts Medical Center
Post-Acute COVID-19
Post COVID-19 Condition
Post Viral Fatigue
Dyspnea
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess
ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2
(PASC) and functional limitations expand
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations Type: Observational Start Date: Jun 2023 |
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to...
ModernaTX, Inc.
COVID-19
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine
efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus
mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2). expand
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2). Type: Interventional Start Date: Mar 2023 |
Understanding COVID-19 Vaccine Immunity in Tissue and Blood
Stanford University
COVID-19 (Coronavirus Disease 2019)
The purpose of this study is to understand the effects of COVID-19 vaccines on the immune
system and how the COVID-19 vaccines provide protection and induce long term memory.
Adults who are receiving a COVID-19 vaccine will be invited to participate in this study. expand
The purpose of this study is to understand the effects of COVID-19 vaccines on the immune system and how the COVID-19 vaccines provide protection and induce long term memory. Adults who are receiving a COVID-19 vaccine will be invited to participate in this study. Type: Observational Start Date: Oct 2024 |
Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
Aetion, Inc.
COVID-19
To apply and compare two different methodological approaches (one applying diagnostics
steps and contingencies and the other not) to the illustrative example described below:
Illustrative Example - Objective I aims to characterize the risk of inpatient mortality
[Primary Outcome] and progression... expand
To apply and compare two different methodological approaches (one applying diagnostics steps and contingencies and the other not) to the illustrative example described below: Illustrative Example - Objective I aims to characterize the risk of inpatient mortality [Primary Outcome] and progression to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) [Secondary Outcome] up to 28 days after interleukin-6 receptor inhibitors (IL6Ri) or janus kinase inhibitor (JAKi) initiation among patients hospitalized with Coronavirus Disease 2019 (COVID-19) who initiate a corticosteroid of interest and require supplemental oxygen / non-invasive ventilation / high flow oxygen (O2/NIV/HFO) (but not IMV/ECMO). Illustrative Example - Objective II aims to characterize the risk of inpatient mortality [Primary Outcome] up to 28 days after IL6Ri or JAKi initiation among patients admitted to the ICU at hospital admission with COVID-19 who initiate a CSI and require IMV/ECMO. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) will be estimated and reported for all outcome risks in Illustrative Example objectives. Type: Observational Start Date: Jun 2020 |
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
Kanecia Obie Zimmerman
Long COVID
Long Covid19
This study is a platform protocol designed to be flexible so that it is suitable for a
wide range of settings within health care systems and in community settings where it can
be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a
prospective, multi-center, multi-arm,... expand
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial with different interventions organized as appendices to the protocol. Each appendix (or sub-study) evaluates potential mechanisms of action, efficacy, and safety of antivirals and other therapeutics in individuals with PASC, according to the platform protocol objectives. The hypothesis is that persistent viral infection, viral reactivation, and/or overactive/chronic immune response and inflammation are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms. Type: Interventional Start Date: Jul 2023 |
Paxlovid for Treatment of Long Covid
Stanford University
Post-acute Sequelae of SARS-CoV-2 Infection
Long COVID
The purpose of this study is to compare whether being treated with nirmatrelvir plus
ritonavir for 15 days works better than being treated with placebo plus ritonavir to
reduce severe symptoms of Long Covid.
Participants will have 5 planned visits to the study clinic over 15 weeks and will take
the... expand
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days. This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for "Long Covid." Type: Interventional Start Date: Nov 2022 |
- Previous
- Next